Submit
an article to
an article to
-
Font Size:
-
Print
- TweetThis
Merrill saying AMAG Pharmaceuticals (AMAG) is worth $21 to $29. They now see potential for a delayed launch until 2011.
This thing could be down 10%+ today.
One Notablecalls Network [NCN] member has some interesting comments on the AMAG downgrade:
It's the third time he has downgraded it in 10 weeks - first Jan. 30 then Feb 28 and now [today]. Nothing new in the report. Also the analyst was hired by Merrill only last year and I think the guy's trying to make a name for himself.Jan. 30 he went from a $100 target to $78 and the stock fell 6 points. Than Feb. 28 he went to Neutral and the stock fell $4 I think.
I'm just saying the whole street knows he has it out for AMAG.
Notablecalls: Excellent color.
Related Articles
|
Comments
1
Comment 1 out of 1
You are viewing the latest 20 comments
-
- Rod Raynovich:
- Comments (5)
- •
- Raygent Capital
- |
- raygent.com
AMAG had a bullet proof business model but it was based upon milestone assumptions one year later.In the meantime the entire former management team bailed at the top~$65/sh. Now the FDA and launch milestone dates are here and the Co. cant deliver. See Yahoo chat on competitition.In the meantime hedgies who moved the stock up from 30 to 70 are getting out.2008 Apr 09 11:23 AM | Link | Reply
Register or Login to rate comments »
Viewing Comment 1 out of 1





















